Jennifer Olivier, MD
Allergy & Immunology · Picayune, MSNPI 1659699726
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi accounts for 71.7% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $16,841, more than ten times the $271 reported in 2019.
Across 433 payments — averaging $54.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$17K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- GSK$814
- CSL Behring$332
- plus $1K from 24 others
What the payments were for
- Consulting fees$13,18756%
- Travel & lodging$1,8908%
- Food & beverage$8,49836%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 59 | $16,965 |
| AstraZeneca | 83 | $1,835 |
| Regeneron Healthcare Solutions, Inc. | 92 | $1,523 |
| Takeda Pharmaceuticals U.S.A., Inc. | 61 | $1,126 |
| GSK | 56 | $814 |
| CSL Behring | 18 | $332 |
| Ionis Pharmaceuticals, Inc. | 9 | $167 |
| Grifols USA, LLC | 8 | $144 |
| Novartis | 7 | $127 |
| Amgen | 4 | $94 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $62 |
| Electromed, Inc. | 8 | $53 |
| Genentech USA, Inc. | 3 | $51 |
| Shire North American Group Inc | 3 | $49 |
| Verona Pharma, Inc. | 2 | $47 |
| Pfizer | 3 | $45 |
| Actelion Pharmaceuticals US, Inc. | 1 | $31 |
| Lilly USA, LLC | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Kedrion Biopharma, Inc. | 1 | $18 |
| Arcutis Biotherapeutics, Inc. | 1 | $18 |
| Incyte Corporation | 1 | $18 |
| Biocryst US Sales Co., LLC | 1 | $17 |
| ADMA Biomanufacturing LLC | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Kaleo, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Bio Products Laboratory USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,673 in reported general payments places this provider in the 70th percentile of 28 allergy & immunology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 25 | $120,131 |
| TezspireTezepelumab-Ekko | 24 | $119,262 |
| NucalaMepolizumab | 25 | $105,942 |
| Dupixent PenDupilumab | 20 | $75,434 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $40,635 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $19,534 |
| Epinephrine | 22 | $5,054 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,211 |
| Azelastine Hcl | 118 | $3,647 |
| Ipratropium Bromide | 65 | $2,647 |
| Doxepin Hcl | 17 | $2,371 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $2,053 |
| Fluticasone Propionate | 62 | $980 |
| Mometasone Furoate | 17 | $613 |
| Doxycycline Hyclate | 34 | $605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,835 | $164,10979 claims |
| GSKNucala, Trelegy Ellipta | $814 | $125,47638 claims |
| CSL BehringHizentra | $332 | $120,13125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 28 allergy & immunology providers in Mississippi.
Other allergy & immunology in Picayune
- Todd AdkinsJackson$226K
- Patricia StewartMadison$215K
- Daniel VenarskeJackson$156K
- Dexter WalcottJackson$154K
- Chelle WilhelmJackson$61K
- Mark MurrayDiberville$41K
- Stephen LeblancMeridian$34K
- Joshua PhillipsJackson$20K
- Matthew OswaltTupelo$13K
- Karen MaltbyTupelo$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.